References
- Accardo A, Mangiapia G, Paduano L, et al. (2013). Octeotride labeled aggregates containing platinum complexes as nanovectors for drug delivery. J Pep Sci 19:190–7
- Aryal S, Hu CMJ, Zhang L. (2012). Synthesis of Ptsome: a platinum-based liposome-like nanostructure. Chem Commun (Camb.) 48:2630–2
- Behrens BC, Hamilton TC, Masuda H, et al. (1987). Characterization of a cis-diamminedichloroplatinum(II)-resistant human ovarian cancer cell line and its use in evaluation of platinum analogues. Cancer Res 47:414–18
- Boulikas T. (2009). Clinical overview on Lipoplatin: a successful liposomal formulation of cisplatin. Expert Opin Investig Drugs 18:1197–218
- Burger KNJ, Staffhorst RWHM, de Kruijff B. (1999). Interaction of the anticancer drug cisplatin with phosphatidylserine in intact and semiintact cells. Biochim Biophys Acta 1419:43–54
- Coluccia M, Nassi A, Boccarelli A, et al. (1999). In vitro antitumour activity and cellular pharmacological properties of the platinum-iminoether complex trans-[PtCl2[E-HN = C(OMe)Me]2]. Int J Oncol 15:1039–44
- de Jonge MJ, Slingerland M, Loos WJ, et al. (2010). Early cessation of the clinical development of LiPlaCis, a liposomal cisplatin formulation. Eur J Cancer 46:3016–21
- Galluzzi L, Senovilla L, Vitale I, et al. (2012). Molecular mechanisms of cisplatin resistance. Oncogene 31:1869–83
- Grit M, Zuidam NJ, Underberg WJM, Crommelin DJA. (1993). Hydrolysis of partially saturated egg phosphatidylcholine in aqueous liposome dispersions and the effect of cholesterol incorporation on hydrolysis kinetics. J Pharm Pharmacol 45:490–5
- Harrington KJ, Lewanski CR, Northcote AD, et al. (2001). Phase I-II study of PEGylated liposomal cisplatin (SPI-077 TM) in patients with inoperable head and neck cancer. Ann Oncol 12:493–6
- Howe-Grant ME, Lippard SJ. (1980). Aqueous platinum(II) chemistry; binding to biological molecules. In: Sigel H, ed. Metal ions in biological systems. Vol. XI. New York: M. Dekker, 63–125
- Kelland L. (2007). The resurgence of platinum-based cancer chemotherapy. Nat Rev Cancer 7:573–84
- Khiati S, Luvino D, Oumzil K, et al. (2011). Nucleoside-lipid-based nanoparticles for cisplatin delivery. ACS Nano 5:8649–55
- Kim ES, Lee JJ, He G, et al. (2012). Tissue platinum concentration and tumor response in non-small-cell lung cancer. J Clin Oncol 30:3345–52
- Lovejoy KS, Lippard SJ. (2009). Non-traditional platinum compounds for improved accumulation, oral bioavailability, and tumour targeting. Dalton Trans 10:651–9
- Matsuzaki K, Murase O, Sugishita K, et al. (2000). Optical characterization of liposomes by right angle light scattering and turbidity measurement. Biochim Biophys Acta 1467:219–26
- Muggia F, Safra T. (2014). 'BRCAness' and its implications for platinum action in gynecologic cancer. Anticancer Res 34:551–6
- Newman MS, Colbern GT, Working PK, et al. (1999). Comparative pharmacokinetics, tissue distribution, and therapeutic effectiveness of cisplatin encapsulated in long-circulating, PEGylated liposomes (SPI-077) in tumor-bearing mice. Cancer Chemother Pharmacol 43:1–7
- Oberoi HS, Nukolova NV, Kabanov AV, Bronich TK. (2013). Nanocarriers for delivery of platinum anticancer drugs. Adv Drug Deliv Rev 65:1667–85
- Reedijk J. (1999). Why does cisplatin reach guanine-N7 with competing s-donor ligands available in the cell? Chem Rev 99:2499–510
- Skehan P, Storeng R, Scudiero D, et al. (1990). New colorimetric cytotoxicity assay for anticancer-drug screening. J Natl Cancer Inst 82:1107–12
- Stathopoulos GP, Boulikas T. (2012). Lipoplatin formulation review article. J Drug Deliv 2012:581363
- Stathopoulos GP, Boulikas T, Kourvetaris A, Stathopoulos J. (2006). Liposomal oxaliplatin in the treatment of advanced cancer: a Phase I study. Anticancer Res 26:1489–93
- Vadiei K, Siddik Z, Khokhar A, et al. (1992). Pharmacokinetics of liposome-entrapped cis-bis-neodecanoato-trans-R, R-1,2-diaminocyclohexane platinum(II) and cisplatin given i.v. and i.p. in the rat. Cancer Chemother Pharmacol 30:365–9
- Wheate NJ, Walker S, Craig GE, Oun R. (2010). The status of platinum anticancer drugs in the clinic and in clinical trials. Dalton Trans 39:8113–27
- Woo J, Chiu NC, Karlssond G, et al. (2008). Use of a passive equilibration methodology to encapsulate cisplatin into preformed thermosensitive liposomes. Int J Pharm 349:38–46